No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
Identifieur interne : 007144 ( Ncbi/Merge ); précédent : 007143; suivant : 007145No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
Auteurs : M. Sladden [Australie] ; S. Zagarella ; C. Popescu ; M. BigbySource :
- The British journal of dermatology [ 1365-2133 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- anatomopathologie : Mélanome, Tumeurs cutanées.
- Biopsie de noeud lymphatique sentinelle, Femelle, Humains, Lymphadénectomie, Mâle.
English descriptors
- KwdEn :
- MESH :
- pathology : Melanoma, Skin Neoplasms.
- Female, Humans, Lymph Node Excision, Male, Sentinel Lymph Node Biopsy.
Abstract
Sentinel lymph node biopsy (SLNB) was developed in the hope that it would improve outcomes for patients with melanoma. SLNB is an area of discussion and controversy in melanoma medicine. The final trial results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) have now been published and the authors suggest their long-term results 'clearly validate the use of sentinel-node biopsy in patients with intermediate-thickness or thick primary melanomas'. An accompanying editorial states that MSLT-I is a practice-changing trial.
DOI: 10.1111/bjd.13675
PubMed: 25776246
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F84
- to stream PubMed, to step Curation: 000F84
- to stream PubMed, to step Checkpoint: 000F84
Links to Exploration step
pubmed:25776246Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.</title><author><name sortKey="Sladden, M" sort="Sladden, M" uniqKey="Sladden M" first="M" last="Sladden">M. Sladden</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Tasmania, 36 Thistle St West, South Launceston, Tasmania, 7249, Australia. m.sladden@doctors.org.uk.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Tasmania, 36 Thistle St West, South Launceston, Tasmania, 7249</wicri:regionArea><wicri:noRegion>7249</wicri:noRegion></affiliation></author><author><name sortKey="Zagarella, S" sort="Zagarella, S" uniqKey="Zagarella S" first="S" last="Zagarella">S. Zagarella</name></author><author><name sortKey="Popescu, C" sort="Popescu, C" uniqKey="Popescu C" first="C" last="Popescu">C. Popescu</name></author><author><name sortKey="Bigby, M" sort="Bigby, M" uniqKey="Bigby M" first="M" last="Bigby">M. Bigby</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25776246</idno><idno type="pmid">25776246</idno><idno type="doi">10.1111/bjd.13675</idno><idno type="wicri:Area/PubMed/Corpus">000F84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F84</idno><idno type="wicri:Area/PubMed/Curation">000F84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F84</idno><idno type="wicri:Area/PubMed/Checkpoint">000F84</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F84</idno><idno type="wicri:Area/Ncbi/Merge">007144</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.</title><author><name sortKey="Sladden, M" sort="Sladden, M" uniqKey="Sladden M" first="M" last="Sladden">M. Sladden</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Tasmania, 36 Thistle St West, South Launceston, Tasmania, 7249, Australia. m.sladden@doctors.org.uk.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Tasmania, 36 Thistle St West, South Launceston, Tasmania, 7249</wicri:regionArea><wicri:noRegion>7249</wicri:noRegion></affiliation></author><author><name sortKey="Zagarella, S" sort="Zagarella, S" uniqKey="Zagarella S" first="S" last="Zagarella">S. Zagarella</name></author><author><name sortKey="Popescu, C" sort="Popescu, C" uniqKey="Popescu C" first="C" last="Popescu">C. Popescu</name></author><author><name sortKey="Bigby, M" sort="Bigby, M" uniqKey="Bigby M" first="M" last="Bigby">M. Bigby</name></author></analytic><series><title level="j">The British journal of dermatology</title><idno type="eISSN">1365-2133</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Female</term><term>Humans</term><term>Lymph Node Excision</term><term>Male</term><term>Melanoma (pathology)</term><term>Sentinel Lymph Node Biopsy</term><term>Skin Neoplasms (pathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie</term><term>Mâle</term><term>Mélanome (anatomopathologie)</term><term>Tumeurs cutanées (anatomopathologie)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Lymph Node Excision</term><term>Male</term><term>Sentinel Lymph Node Biopsy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sentinel lymph node biopsy (SLNB) was developed in the hope that it would improve outcomes for patients with melanoma. SLNB is an area of discussion and controversy in melanoma medicine. The final trial results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) have now been published and the authors suggest their long-term results 'clearly validate the use of sentinel-node biopsy in patients with intermediate-thickness or thick primary melanomas'. An accompanying editorial states that MSLT-I is a practice-changing trial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25776246</PMID><DateCreated><Year>2015</Year><Month>03</Month><Day>17</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2133</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The British journal of dermatology</Title><ISOAbbreviation>Br. J. Dermatol.</ISOAbbreviation></Journal><ArticleTitle>No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.</ArticleTitle><Pagination><MedlinePgn>566-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjd.13675</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sentinel lymph node biopsy (SLNB) was developed in the hope that it would improve outcomes for patients with melanoma. SLNB is an area of discussion and controversy in melanoma medicine. The final trial results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) have now been published and the authors suggest their long-term results 'clearly validate the use of sentinel-node biopsy in patients with intermediate-thickness or thick primary melanomas'. An accompanying editorial states that MSLT-I is a practice-changing trial.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">However, critical appraisal of MSLT-I data does not support the claims of the final report. On the contrary, MSLT-I failed to demonstrate that there is a significant treatment-related difference in the 10-year melanoma-specific survival rate in the overall study population. Furthermore, there was no improvement in overall or melanoma-specific survival of the intermediate-thickness group (1·2-3·5 mm). Completion lymphadenectomy can result in complications in about a third of patients, with a rate of clinically significant lymphoedema following axillary or groin dissection of 5-10%. Unnecessary lymphadenectomy can therefore have a major effect on patient quality of life. The evidence provided by Morton et al. does not support the claim that sentinel lymph node biopsy followed by lymphadenectomy in patients with positive sentinel nodes should be the standard of care in patients with melanoma. Readers are encouraged to check with registration sites to make sure declared primary outcomes are fairly reported. Post-hoc analyses are at best exploratory and cannot be used to form the principal conclusions of a trial.</AbstractText><CopyrightInformation>© 2015 British Association of Dermatologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sladden</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Tasmania, 36 Thistle St West, South Launceston, Tasmania, 7249, Australia. m.sladden@doctors.org.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagarella</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Popescu</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bigby</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Dermatol</MedlineTA><NlmUniqueID>0004041</NlmUniqueID><ISSNLinking>0007-0963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Dermatol. 2015 Mar;172(3):571-3</RefSource><PMID Version="1">25776247</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2014 Feb 13;370(7):599-609</RefSource><PMID Version="1">24521106</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="Y">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021701" MajorTopicYN="Y">Sentinel Lymph Node Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25776246</ArticleId><ArticleId IdType="doi">10.1111/bjd.13675</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Bigby, M" sort="Bigby, M" uniqKey="Bigby M" first="M" last="Bigby">M. Bigby</name><name sortKey="Popescu, C" sort="Popescu, C" uniqKey="Popescu C" first="C" last="Popescu">C. Popescu</name><name sortKey="Zagarella, S" sort="Zagarella, S" uniqKey="Zagarella S" first="S" last="Zagarella">S. Zagarella</name></noCountry><country name="Australie"><noRegion><name sortKey="Sladden, M" sort="Sladden, M" uniqKey="Sladden M" first="M" last="Sladden">M. Sladden</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007144 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 007144 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25776246
|texte= No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25776246" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |